Holen Sie sich die Stockscreener-App
0.5328
4.86%
-0.0272
Schlusskurs vom Vortag:
$0.56
Offen:
$0.5499
24-Stunden-Volumen:
2.14M
Relative Volume:
0.63
Marktkapitalisierung:
$57.12M
Einnahmen:
$11.16M
Nettoeinkommen (Verlust:
$-148.13M
KGV:
-0.3354
EPS:
-1.5885
Netto-Cashflow:
$-112.35M
1W Leistung:
+13.39%
1M Leistung:
-58.70%
6M Leistung:
-76.42%
1J Leistung:
-78.69%
1-Tages-Spanne:
$0.5328
$0.5768
1-Wochen-Bereich:
$0.4594
$0.5768
52-Wochen-Spanne:
$0.4425
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
Firmenname
Caribou Biosciences Inc
Sektor
Branche
Telefon
510-982-6030
Adresse
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
0.5328 | 57.12M | 11.16M | -148.13M | -112.35M | -1.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-08 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2026-10-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-10-07 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-06-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-08 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2023-10-31 | Eingeleitet | Evercore ISI | Outperform |
| 2023-07-11 | Eingeleitet | Truist | Buy |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-17 | Eingeleitet | BofA Securities | Buy |
| 2021-08-17 | Eingeleitet | Citigroup | Neutral |
| 2021-08-17 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Caribou Biosciences Inc Aktie (CRBU) Neueste Nachrichten
Arcus Biosciences stock falls on public offering announcement - Yahoo Finance Australia
Caribou Biosciences (CRBU) Slides 6.44% to $0.46 as Shares Test Key SupportRVOL Breakout - https://www.siam.in/
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
OLB Group (OLB) Rally Cools After Hours as Shares Tumble 29%: Here's Why - Benzinga
Caribou alarm herd, stock plunges on ‘alternatives’ plan - BioWorld News
OLB Group (OLB) Rally Cools After Hours as Shares Tumble 29%: Here's Why - TradingView
A director receives 14,000 Kyntra Bio (KYNB) stock options with a $6.50 exercise price. - Stock Titan
Caribou Biosciences stock plunges 40% on halt of CAR-T programs - Investing.com
500,000 option-exercise shares are part of an officer's planned sale at Pacific Biosciences (PACB). - Stock Titan
A director converts a stock grant and holds 141,585 Solid Biosciences (SLDB) shares directly. - Stock Titan
Option exercises are part of a CEO's proposed share sale at IDEAYA (Nasdaq: IDYA). - Stock Titan
Constellation Brands Inc (STZ) Stock Price, Quote, News & History - Benzinga
After buying 5,500 shares, Anixa Biosciences (ANIX) CFO holds 50,000 shares directly. - Stock Titan
The NYSE notifies regulators of plans to remove Global Business Travel (NYSE: GBTG) Class A shares. - Stock Titan
Over 5% stake disclosed in Harvard Bioscience (HBIO) - Stock Titan
TuHURA Biosciences (Nasdaq:HURA)Stock Analysis - Simply Wall Street
Caribou Biosciences (NasdaqGS:CRBU) Stock Price - Simply Wall Street
Upstream Bio (UPB) CEO share sale used to cover taxes - Stock Titan
Performance grant hands 4,483 shares to Neurocrine (NBIX) regulatory chief - Stock Titan
Director’s trust at Inhibrx (NASDAQ: INBX) logs four 500-share stock sales - Stock Titan
Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - finance.yahoo.com
Anixa Biosciences (NASDAQ: ANIX) CEO lifts stake to 665,000 shares - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
Aquestive Therapeutics (AQST) CEO boosts stake with warrant exercise - Stock Titan
OUTFRONT Media (NYSE: OUT) officer plans $100.9K Rule 144 stock sale - Stock Titan
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now - TradingView
Interpace Biosciences will reduce outstanding shares from ~27.7M to ~5.5M - Stock Titan
Caribou (CRBU) Today: Gains 3.11% to Reach $1.66 at the Close; Key Range: $1.58 and $1.74 Define the Nearby Reference Levels under the Current SnapshotVOLD Alert - vinanet.vn
Caribou (CRBU) Today: Gains 3.11% to Reach $1.66 at the Close; Key Range: $1.58 and $1.74 Define the Nearby Reference Levels under the Current SnapshotVolatility Stop - careplusvn.com
Caribou (CRBU) Today: Gains 3.11% to Reach $1.66 at the Close; Key Range: $1.58 and $1.74 Define the Nearby Reference Levels under the Current SnapshotValue Stock Ideas - siam.in
Caribou (CRBU) Quarterly Figures: EPS Comes in Above Forecast in the Latest Reading; Share Move - vinanet.vn
Caribou (CRBU) Quarterly Figures: EPS Comes in Above Forecast in the Latest Reading; Share Move - vinanet.vn
3i injects cash into Valion Bio (VBIO) under tight ownership cap - Stock Titan
PubMatic (NASDAQ: PUBM) details latest insider stock trade - Stock Titan
Caribou Biosciences (CRBU) Slips 1.86% to $1.58 as Gene-Editing Stock Tests Key Support LevelPut Wall - dars.gov.et
Caribou Biosciences (CRBU) Slips 1.86% to $1.58 as Gene-Editing Stock Tests Key Support LevelDark Pool Prints - vinanet.vn
Caribou Biosciences (CRBU) Slips 1.86% to $1.58 as Gene-Editing Stock Tests Key Support LevelPut Wall - dars.gov.et
Caribou Biosciences (CRBU) Slips 1.86% to $1.58 as Gene-Editing Stock Tests Key Support LevelAAII Bearish - dars.gov.et
Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Caribou Biosciences (NASDAQ:CRBU) Price Target Cut to $5.00 by Analysts at Bank of America - MarketBeat
Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Caribou Biosciences, Inc. Stock 12‑Month Price Target Cut to $11.86, Implies 636% Upside - TradingView
Caribou Biosciences earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria
Caribou Biosciences earnings beat by $0.07, revenue topped estimates - Investing.com Canada
Caribou Biosciences (NASDAQ:CRBU) Releases Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Caribou Biosciences Q2 EPS beats estimate, sales miss - scanx.trade
Form 8K Caribou Biosciences Inc For: 13 August By Investing.com - Investing.com Australia
Caribou Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CARIBOU BIOSCIENCES ($CRBU) Releases Q2 2026 Earnings - Quiver Quantitative
Finanzdaten der Caribou Biosciences Inc-Aktie (CRBU)
Umsatz
Nettogewinn
Free Cashflow
ENV
Caribou Biosciences Inc-Aktie (CRBU) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| TIMOTHY KELLY | Officer |
Feb 25 '26 |
Proposed Sale |
1.93 |
6,228 |
12,051 |
0 |
| BARBARA G MCCLUNG | Officer |
Feb 24 '26 |
Proposed Sale |
1.96 |
6,938 |
13,598 |
0 |
| RUHI AHMAD KHAN | Officer |
Feb 24 '26 |
Proposed Sale |
1.96 |
6,938 |
13,598 |
0 |
| MCCLUNG BARBARA G | Chief Legal Officer |
Feb 24 '26 |
Sale |
1.96 |
6,938 |
13,598 |
481,564 |
| Khan Ruhi Ahmad | Chief Business Officer |
Feb 24 '26 |
Sale |
1.96 |
6,938 |
13,598 |
104,998 |
| Albertson Tina M. | Chief Medical Officer |
Feb 24 '26 |
Sale |
1.96 |
1,066 |
2,089 |
68,523 |
| Kelly Timothy P | Chief Technology Officer |
Feb 24 '26 |
Sale |
1.96 |
3,147 |
6,168 |
79,353 |
3.09%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):